---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-25-000040"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T13:41:36.773608+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Recursion appoints former FDA Principal Deputy Commissioner Dr. Bumpus and Mammoth Biosciences COO/CFO Sun to board

## Summary
- Elaine Sun and Dr. Namandjé Bumpus appointed to Board effective March 15, 2025, expanding board from 8 to 10.
- Dr. Bumpus served as FDA Principal Deputy Commissioner until Dec 2024, brings regulatory and AI-in-science expertise.
- Elaine Sun is COO/CFO of Mammoth Biosciences, ex-CFO of Halozyme, with 30 years life sciences finance experience.
- New committees: R&D and Technology; Sun chairs Audit, Bumpus joins Nominating, R&D, and Technology committees.
- Director compensation policy amended to cover new committee roles.

## SEC filing metadata
- accession: 0001601830-25-000040
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183025000040/0001601830-25-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183025000040/rxrx-20250315.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-25-000040
- JSON: https://secwatch.observer/filing/0001601830-25-000040.json
- Plain text: https://secwatch.observer/filing/0001601830-25-000040.txt

## Source-grounded claims
- claim_id: 03be3c1dd6
  claim: Elaine Sun was appointed as Director at RECURSION PHARMACEUTICALS, INC..
  evidence_excerpt: The Board appointed Ms. Sun as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as the Chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183025000040/0001601830-25-000040-index.htm
- claim_id: a237a18340
  claim: Dr. Namandjé Bumpus was appointed as Director at RECURSION PHARMACEUTICALS, INC..
  evidence_excerpt: The Board appointed Dr. Bumpus as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as a member of the Nominating Committee of the Board, the Research and Development Committee of the Board, and the Technology Committee of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183025000040/0001601830-25-000040-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.